Pictilisib | GDC-0941 | PI3Kα/δ Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / PI3K / Pictilisib

Pictilisib {[allProObj[0].p_purity_real_show]}

货号：A198456 同义名： GDC-0941; GNE-0941

Pictilisib（GDC-0941）是一种有效的PI3Kα/δ抑制剂，IC50为3 nM，对p110β（11倍）和p110γ（25倍）具有适度选择性。

Pictilisib 化学结构
CAS号：957054-30-7

Pictilisib 3D分子结构
CAS号：957054-30-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Pictilisib 纯度/质量文件产品仅供科研

货号：A198456 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

PI3K 亚型比较

产品名称	C2β ↓ ↑	p110α ↓ ↑	p110β ↓ ↑	p110γ ↓ ↑	p110δ ↓ ↑	PI3K ↓ ↑	Vps34 ↓ ↑	其他靶点	纯度
A66	+ C2β, IC50: 462 nM	++ p110α, IC50: 32 nM							99%+
Taselisib	+ C2β, IC50: 292 nM	++++ PI3Kα, Ki: 0.29 nM	+++ PI3Kβ, Ki: 9.1 nM	++++ PI3Kγ, Ki: 0.97 nM	++++ PI3Kδ, Ki: 0.12 nM		+ hVps34, IC50: 374 nM		99%+
Gedatolisib		++++ PI3Kα, IC50: 0.4 nM		+++ PI3Kγ, IC50: 5.4 nM				mTOR	99%
HS-173		++++ PI3Kα , IC50: 0.8 nM							99%+
Serabelisib		+++ PI3Kα, IC50: 21 nM							99%+
GNE-477		++++ PI3Kα, IC50: 4 nM						mTOR	99%
YM-201636		+ p110α, IC50: 3.3 μM						PIKfyve	98%
AS-252424		+ PI3Kα, IC50: 935 nM		++ PI3Kγ, IC50: 33 nM					99%
Alpelisib		+++ PI3Kα, IC50: 5 nM							99%+
AS-604850		+ PI3Kα, IC50: 4.5 μM		+ PI3Kγ, IC50: 0.25 μM					99%
SF2523		++ PI3Kα, IC50: 34 nM		++ PI3Kγ, IC50: 158 nM				DNA-PK,mTOR	99%+
Inavolisib		++++ PI3K alpha, IC50: 0.038 nM							99%+
Bimiralisib		++++ PI3Kα, Kd: 1.5 nM	+++ PI3Kβ, Kd: 11 nM	++ PI3Kγ, Kd: 25 nM	++ PI3Kδ, Kd: 25 nM			mTOR	99%+
GSK1059615		++++ PI3Kα, IC50: 0.4 nM	++++ PI3Kβ, IC50: 0.6 nM	+++ PI3Kγ, IC50: 5 nM	++++ PI3Kδ, IC50: 2 nM			mTOR	98%
GSK2636771			✔						99%
Fimepinostat		+++ PI3Kα, IC50: 19 nM	++ PI3Kβ, IC50: 54 nM		++ PI3Kδ, IC50: 39 nM				99%+
VS-5584		++++ PI3Kα, IC50: 2.6 nM	+++ PI3Kβ, IC50: 21 nM	++++ PI3Kγ, IC50: 3.0 nM	++++ PI3Kδ, IC50: 2.7 nM			mTOR	98%
Dactolisib		++++ p110α1, IC50: 4 nM	++ p110β, IC50: 75 nM	+++ p110γ, IC50: 5 nM	+++ p110δ, IC50: 7 nM				98+%
PI-103		++++ p110α, IC50: 2 nM	++++ p110β, IC50: 3 nM	+++ p110γ, IC50: 15 nM	++++ p110δ, IC50: 3 nM			DNA-PK,mTOR	99%+
PI-3065			+ p110β, IC50: 1078 nM		+++ p110δ, IC50: 15 nM				99%+
Voxtalisib		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	99%+
AZD-8835		+++ PI3Kα, IC50: 6.2 nM	+ PI3Kβ, IC50: 431 nM	++ PI3Kγ, IC50: 90 nM	+++ PI3Kδ, IC50: 5.7 nM				99%
Pilaralisib analogue		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 36 nM	+++ PI3Kγ, IC50: 23 nM	++ PI3Kδ, IC50: 36 nM				99%+
ZSTK474		+++ PI3Kα, IC50: 16 nM	++ PI3Kβ, IC50: 44 nM	++ PI3Kγ, IC50: 49 nM	+++ PI3Kδ, IC50: 4.6 nM	++ PI3K, IC50: 37 nM			98%
AS-605240		++ PI3Kα, IC50: 60 nM	+ PI3Kβ, IC50: 270 nM	+++ PI3Kγ, IC50: 8 nM	+ PI3Kδ, IC50: 300 nM				98%
TGX-221			+++ p110β, IC50: 5 nM		++ p110δ, IC50: 0.1 μM				99%+
PF-04691502		++++ PI3Kα, Ki: 1.8 nM	++++ PI3Kβ, Ki: 2.1 nM	++++ PI3Kγ, Ki: 1.9 nM	++++ PI3Kδ, Ki: 1.6 nM			mTOR	98+%
GDC-0084		++++ PI3Kα, Ki app: 2 nM	++ PI3Kβ, Ki app: 46 nM	+++ PI3Kγ, Ki app: 10 nM	++++ PI3Kδ, Ki app: 3 nM			mTOR	99%+
Buparlisib		++ p110α, IC50: 52 nM	+ p110β, IC50: 166 nM	+ p110γ, IC50: 262 nM	++ p110δ, IC50: 116 nM		+ Vps34, IC50: 2.4 μM	mTOR	98%
LY294002		+ p110α, IC50: 0.5 μM	+ p110β, IC50: 0.97 μM		+ p110δ, IC50: 0.57 μM			DNA-PK	99%+
AZD 6482		+ PI3Kα, IC50: 870 nM	+++ PI3Kβ, IC50: 10 nM		++ PI3Kδ, IC50: 80 nM			DNA-PK	99%+
Pictilisib		++++ p110α, IC50: 3 nM	++ p110β, IC50: 33 nM	++ p110γ, IC50: 75 nM	++++ p110δ, IC50: 3 nM			mTOR	99%+
PKI-402		++++ PI3Kα, IC50: 2 nM	+++ PI3Kβ, IC50: 7 nM	+++ PI3Kγ, IC50: 16 nM	+++ PI3Kδ, IC50: 14 nM			mTOR	98%
Copanlisib		++++ PI3Kα, IC50: 0.5 nM	++++ PI3Kβ, IC50: 3.7 nM	+++ PI3Kγ, IC50: 6.4 nM	++++ PI3Kδ, IC50: 0.7 nM				99%+
Omipalisib		++++ p110α, Ki: 0.019 nM	++++ p110β, Ki: 0.13 nM	++++ p110γ, Ki: 0.06 nM	++++ p110δ, Ki: 0.024 nM				99%+
Izorlisib		+++ PI3Kα, IC50: 14 nM	++ PI3Kβ, IC50: 0.12 μM	++ PI3Kγ, IC50: 36 nM	+ PI3Kδ, IC50: 0.50 μM				99%+
AZD8186		++ PI3Kα, IC50: 35 nM	++++ PI3Kβ, IC50: 4 nM		+++ PI3Kδ, IC50: 12 nM				99%
KU-0060648		++++ PI3Kα, IC50: 4 nM	++++ PI3Kβ, IC50: 0.5 nM	+ PI3Kγ, IC50: 0.59 μM	++++ PI3Kδ, IC50: 0.1 nM			DNA-PK	98%
Apitolisib		+++ p110α, IC50: 5 nM	++ p110β, IC50: 27 nM	+++ p110γ, IC50: 14 nM	+++ p110δ, IC50: 7 nM			mTOR	98%+
CZC24832			+ PI3Kβ, IC50: 1.1 μM	++ PI3Kγ, IC50: 27 nM					98+%
BGT226 maleate		++++ PI3Kα, IC50: 4 nM	++ PI3Kβ, IC50: 63 nM	++ PI3Kγ, IC50: 38 nM				mTOR	99%+
TG 100713		++ PI3Kα, IC50: 165 nM	+ PI3Kβ, IC50: 215 nM	++ PI3Kγ, IC50: 50 nM	+++ PI3Kδ, IC50: 24 nM				98%+
PI3K-IN-1		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	98+%
TG100-115		+ PI3Kα, IC50: 1.3 μM	+ PI3Kβ, IC50: 1.2 μM	++ PI3Kγ, IC50: 83 nM	+ PI3Kδ, IC50: 235 nM				98%
PIK-90		+++ PI3Kα, IC50: 11 nM	+ PI3Kβ, IC50: 350 nM	+++ PI3Kγ, IC50: 18 nM	++ PI3Kδ, IC50: 58 nM				99%+
PIK-294			+ p110β, IC50: 490 nM	++ p110γ, IC50: 160 nM	+++ p110δ, IC50: 10 nM				99%+
Duvelisib			++++ PI3Kβ, Ki: 1564 pM	++ PI3Kγ, Ki: 243 pM	++++ PI3Kδ, Ki: 23 pM				99%+
GDC-0326		++++ PI3Kα, Ki: 0.2 nM	++ PI3Kβ, Ki: 26.6 nM	+++ PI3Kγ, Ki: 10.2 nM	++++ PI3Kδ, Ki: 4 nM				98%
Quercetin Dihydrate			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM				95%
Quercetin			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM			Sirtuin,Src,PKC	95%
Leniolisib		+ PI3Kα, IC50: 0.244 μM	+ PI3Kβ, IC50: 0.424 μM	+ PI3Kγ, IC50: 2.23 μM	+++ PI3Kδ, IC50: 0.011 μM			DNA-PK	99%+
PIK-108			✔						99%
Eganelisib				+++ PI3Kγ, IC50: 16 nM					99%+
CAY10505				✔					99%
IPI-3063					++++ p110δ, IC50: 2.5 nM				99%
Nemiralisib					++++ PI3Kδ, pKi: 9.9				99%+
PF-4989216		++++ p110α, IC50: 2 nM		++ p110γ, IC50: 65 nM	++++ p110δ, IC50: 1 nM				99%+
PIK-75 HCl		+++ p110α, IC50: 5.8 nM		++ p110γ, IC50: 76 nM	+ p110δ, IC50: 0.51 μM			DNA-PK	99%+
Tenalisib				++ PI3Kγ, IC50: 33.2 nM	++ PI3Kδ, IC50: 24.5 nM				98%
Acalisib					+++ p110δ, IC50: 14 nM				99%+
Umbralisib					+++ PI3Kδ, IC50: 22.2 nM				99%+
AMG319				+ PI3Kγ, IC50: 850 nM	+++ PI3Kδ, IC50: 18 nM				99%
IC-87114				+ PI3Kγ, IC50: 29 μM	+ PI3Kδ, IC50: 0.5 μM				99%+
Idelalisib				++ p110γ, IC50: 89 nM	++++ p110δ, IC50: 2.5 nM				98%
PIK-293				+ p110γ, IC50: 10 μM	+ p110δ, IC50: 0.24 μM				99%+
Vps34-PIK-III					+ PI3Kδ, IC50: 1.2μM		+++ Vps34, IC50: 0.018μM		99%+
GSK2292767					✔				98%
Seletalisib				+ PI3Kγ, IC50: 282 nM	+++ PI3Kδ, IC50: 12 nM				99%+
P110δ-IN-1					++++ P110δ, IC50: 0.6 nM				99%
PI3Kδ-IN-5					++++ PI3Kδ, IC50: 0.9 nM				99%
SRX3207		+ PI3K alpha, IC50: 244 nM		+ PI3K gamma, IC50: 9790 nM	+ PI3K delta, IC50: 388 nM			Syk	98%
Parsaclisib HCl					++++ PI3Kδ, IC50: 1 nM				98%
IHMT-PI3Kδ-372					+++ PI3Kδ, IC50: 14 nM				98%
Trigonelline						✔		Akt	99%+
Wortmannin						++++ PI3K, IC50: 3 nM		DNA-PK,MLCK	99%+
Samotolisib						✔		DNA-PK	99%+
GNE-317						✔			99%+
Oroxin B						✔		Akt,PTEN	99%+
NU 7026						+ PI3K, IC50: 13 μM		DNA-PK	98+%
Deguelin						✔		Akt	99%+
Ailanthone						✔		Akt,CDK,ATM/ATR	98%
Resibufogenin						✔		ROS	98%
KU-57788						+ PI3K, IC50: 5 μM		DNA-PK,mTOR	99%+
Cinobufagine						✔		Akt	99%
α-Linolenic acid						✔			97% (GC)
MTX-211						✔		EGFR	98%
PI3K/mTOR Inhibitor-2						++++ PI3K, IC50: 3.4 nM		mTOR	99%+
SPP-86						✔			99%+
(E)-Akt inhibitor-IV						✔			98%
Vps34-IN-1							++ Vps34, IC50: 25 nM		98%
SAR405							++++ Vps34, IC50: 1.2 nM		98+%
3-Methyladenine				+ PI3Kγ, IC50: 60 μM			+ Vps34, IC50: 25 μM	Autophagy	98%
Vps34-IN-4							+++ VPS34, IC50: 15 nM		98%+
Autophinib							+++ Vps34, IC50: 19 nM	Autophagy	99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Pictilisib 生物活性

靶点	p110γ p110γ, IC50:75 nM p110β p110β, IC50:33 nM p110α p110α, IC50:3 nM p110δ p110δ, IC50:3 nM
描述	Phosphatidylinositol-3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of the 3-hydroxyl position of phosphatidylinositides and participate in several cellular process. Up to now, there are eight PI3 kinases have been identified, which are divided into classes IA, 1B, II, and III based on the sequence homology and substrate preference. GDC-0941 is a potent, selective and orally bioavailable inhibitor of class I PI3Ks (p110α IC50=3nM, p110δ IC50=3nM, p110β IC50=33nM, p110γ IC50=75nM, measured by scintillation proximity assay), with less potency to mTOR (IC50=0.58μM, measured by HTRF assay)^[1]. GDC-0941 is a derivative of PI-103, a dual PI3K/mTOR inhibitor, and has good pharmacokinetic properties. Its oral bioavailability is up to 78% in subcutaneous U-87 MG xenograft mice and shows sustained and remarkable inhibition of Akt phosphorylation and tumor growth, up to 98%^[2]. GDC-0941 barely penetrated through the intact BBB^[3].
作用机制	GDC-0941 is a potent, ATP competitive inhibitor of p110α with Ki value of 10.2±4.4 nM.^[1]

Pictilisib 细胞实验

Cell Line Human NK cells MEB-Med-8A cells Daoy cells KPwmC cells P14 CD8+ T cells SW48-HER2 LIM1215-HER2 SW48-HER2 cells LIM1215-HER2 cells mIMCD3 cells AML12 cells NIH3T3 cells	Concentration	Treated Time	Description	References
Human NK cells	1 μM	2 hours	To evaluate the effect of MLN1117 on human NK cell-mediated cytotoxicity. Results showed that selective inhibition of p110α had minimal impact on human NK cell-mediated cytotoxicity.	PLoS One. 2014 Jun 10;9(6):e99486.
MEB-Med-8A cells	1 μM	24 h	Pictilisib significantly inhibited the migration of MEB-Med-8A cells and altered the cytoskeleton structure.	J Cell Mol Med. 2022 Dec;26(23):5832-5845.
Daoy cells	1 μM	24 h	Pictilisib reduced the migration of Daoy cells, significantly decreased wound closure, and altered the cytoskeleton structure.	J Cell Mol Med. 2022 Dec;26(23):5832-5845.
KPwmC cells	1μM	30 min	To observe the effect of Pictilisib on p-CREB1S133 levels, results showed that Pictilisib reduced p-CREB1S133 levels.	Cancer Discov. 2021 Aug;11(8):2094-2111.
P14 CD8+ T cells	1 μM	3 to 4 days	Inhibition of PI3K activity, leading to defective CD3 polarity and Glut1 surface trafficking, reduced glucose uptake	Cell Rep. 2018 Jan 23;22(4):860-868.
SW48-HER2	0.05 to 10 μM	96 h	To evaluate the anti-proliferative effects of Pictilisib on SW48-HER2 cells. Results showed that Pictilisib as a single agent exhibited dose-dependent cell growth inhibition in HER2-amplified cells.	J Exp Clin Cancer Res. 2019 Jun 4;38(1):236.
LIM1215-HER2	0.05 to 10 μM	96 h	To evaluate the anti-proliferative effects of Pictilisib on LIM1215-HER2 cells. Results showed that Pictilisib as a single agent exhibited dose-dependent cell growth inhibition in HER2-amplified cells.	J Exp Clin Cancer Res. 2019 Jun 4;38(1):236.
SW48-HER2 cells	0.05 to 10 μM	96 h	To evaluate the inhibitory effect of Pictilisib on cell proliferation, the results showed that Pictilisib monotherapy exhibited dose-dependent growth inhibition in HER2-amplified cells.	J Exp Clin Cancer Res. 2019 Jun 4;38(1):236.
LIM1215-HER2 cells	0.05 to 10 μM	96 h	To evaluate the inhibitory effect of Pictilisib on cell proliferation, the results showed that Pictilisib monotherapy exhibited dose-dependent growth inhibition in HER2-amplified cells.	J Exp Clin Cancer Res. 2019 Jun 4;38(1):236.
mIMCD3 cells	1 µM	10 h	Pictilisib significantly reduced phosphorylation of Akt, MAPKAP1, and GFAP, and increased the formation of Dendra2 CMA reporter puncta, indicating an increase in CMA activity.	J Cell Biol. 2020 Dec 7;219(12):e202001031.
AML12 cells	2 µM	10 h	Pictilisib significantly reduced phosphorylation of Akt, MAPKAP1, and GFAP, and increased the formation of Dendra2 CMA reporter puncta, indicating an increase in CMA activity.	J Cell Biol. 2020 Dec 7;219(12):e202001031.
NIH3T3 cells	500 nM	10 h	Pictilisib significantly reduced phosphorylation of Akt, MAPKAP1, and GFAP, and increased the accumulation of Dendra2 CMA reporter puncta, indicating an increase in CMA activity.	J Cell Biol. 2020 Dec 7;219(12):e202001031.

Pictilisib 动物实验

Species Mice Nude mice Nude mice Mice Mice	Animal Model T-ALL JW81 model LIM1215-HER2 and SW48-HER2 tumor xenograft models LIM1215-HER2 and SW48-HER2 tumor xenografts Normal 3-month-old mice MR86 patient-derived xenograft (PDX) model	Administration	Dosage	Frequency	Description	References
Mice	T-ALL JW81 model	Oral and intraperitoneal injection	100 mg/kg/day	GDC0941 once daily, VCR twice weekly, until mice developed progressive disease	To evaluate the efficacy of GDC0941 and VCR combination therapy in T-ALL mouse model	Cell Rep. 2019 Apr 9;27(2):631-647. e5
Nude mice	LIM1215-HER2 and SW48-HER2 tumor xenograft models	Oral	75 mg/kg	Once daily for 4 weeks	To evaluate the antitumor activity of Pictilisib in LIM1215-HER2 and SW48-HER2 tumor xenograft models. Results showed that Pictilisib as a single agent had little effect on tumor growth, but the combination with Refametinib almost completely suppressed tumor growth.	J Exp Clin Cancer Res. 2019 Jun 4;38(1):236.
Nude mice	LIM1215-HER2 and SW48-HER2 tumor xenografts	Oral	75 mg/kg	Every day, for 4 weeks	To evaluate the inhibitory effect of Pictilisib monotherapy and its combination with Refametinib on tumor growth, the results showed that the combination therapy significantly suppressed tumor growth and lasted up to 20 weeks after the end of treatment.	J Exp Clin Cancer Res. 2019 Jun 4;38(1):236.
Mice	Normal 3-month-old mice	Oral	100 mg/kg	Once per day for 7 days	Pictilisib significantly increased CMA substrate uptake in liver lysosomes and reduced lysosomal GFAP phosphorylation in mice, indicating an increase in CMA activity.	J Cell Biol. 2020 Dec 7;219(12):e202001031.
Mice	MR86 patient-derived xenograft (PDX) model	Oral	150 mg/kg	Once daily for up to 40 days	To evaluate the inhibitory effect of Pictilisib in combination with Erdafitinib on tumor growth, the results showed that the combination treatment significantly inhibited tumor growth	Cancer Discov. 2023 Sep 6;13(9):1998-2011

Pictilisib 动物研究

Dose	Mice: min = 75 mg/kg^[4], max = 150 mg/kg^[5] Nude Mice: min = 25 mg/kg bid, max = 50 mg/kg bid^[6]
Administration	p.o

Pictilisib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02430363	Glioblastoma	Phase 1 Phase 2	Unknown	June 2018	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Belgium UCL- Cliniques Universitaires Saint Luc Brussels, Belgium Germany St Johannes Hospital Duisburg, Germany, 47166 Italy Spedali Civili di Brescia Brescia, Italy IRCCS San Raffaele Milan, Italy Poland Lower-Silesian Oncology Centre Wroclaw, Lower-Silesian, Poland, 53413 Russian Federation Pavlov State Medical University St. Petersburg, Russian Federation, 197089 Spain Hospital Universitario Germans Trias I Pujol Barcelona,, Spain Switzerland Universitätsklinik für Frauenheilkunde Bern, Switzerland Ukraine Regional Cancer Center Dnepropetrovsk, Ukraine, 49000 National Institute of Cancer Kiev, Ukraine, 03035 United Kingdom Royal Victoria Hospital Belfast, Ulster, United Kingdom, BT12 6BA 收起 <<
NCT02389842	Advanced Solid Tumours ... 展开 >> Breast Cancer 收起 <<	Phase 1	Unknown	August 2017	United Kingdom ... 展开 >> The Royal Marsden NHS Foundation Trust Recruiting London, United Kingdom, SM2 5PT Contact: Timothy Yap, PhD 02086613539 timothy.yap@icr.ac.uk Principal Investigator: Timothy Yap, PhD The Christie NHS Foundation Trust Not yet recruiting Manchester, United Kingdom, M20 4BX Contact: Anne Amstrong, MBBS 0161 446 3746 elaine.mercer@christie.nhs.uk Principal Investigator: Anne Armstrong, MBBS 收起 <<
NCT02092831	Healthy Volunteer	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Madison, Wisconsin, United States, 53704 收起 <<

Pictilisib 参考文献

[1]Folkes AJ, Ahmadi K, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d] pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem. 2008 Sep 25;51(18):5522-32.

[2]Raynaud FI, Eccles SA, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-38.

[3]Salphati L, Shahidi-Latham S, et al. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Drug Metab Dispos. 2014 Jul;42(7):1110-6.

[4]Garcia-Martínez JM, Wullschleger S, et al. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer. 2011;104(7):1116-25.

[5]Wallin JJ, Guan J, et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res. 2012;18(14):3901-11.

[6]Burrows N, Babur M, et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways. J Clin Endocrinol Metab. 2011;96(12):E1934-43.

Pictilisib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.19mL

9.73mL

1.95mL

0.97mL

19.47mL

3.89mL

1.95mL

Pictilisib 技术信息

CAS号	957054-30-7
分子式	C₂₃H₂₇N₇O₃S₂
分子量	513.64
SMILES Code	CS(=O)(=O)N1CCN(CC2=CC3=C(S2)C(=NC(=N3)C2=C3C=NNC3=CC=C2)N2CCOCC2)CC1
MDL No.	MFCD11616196

别名	GDC-0941; GNE-0941; Pictrelisib; RG7321
运输	蓝冰
InChI Key	LHNIIDJUOCFXAP-UHFFFAOYSA-N
Pubchem ID	17755052

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

细胞实验：

DMSO: 105 mg/mL(204.43 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

p110γ	p110γ, IC50:75 nM
p110β	p110β, IC50:33 nM
p110α	p110α, IC50:3 nM
p110δ	p110δ, IC50:3 nM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

22RV1		Growth Inhibition Assay		IC50=2.45617 μM	SANGER
5637		Growth Inhibition Assay		IC50=2.71035 μM	SANGER
639-V		Growth Inhibition Assay		IC50=1.50245 μM	SANGER
647-V		Growth Inhibition Assay		IC50=4.44022 μM	SANGER
697		Growth Inhibition Assay		IC50=831.55 nM	SANGER
769-P		Growth Inhibition Assay		IC50=3.82743 μM	SANGER
786-0		Growth Inhibition Assay		IC50=2.59238 μM	SANGER
8305C		Growth Inhibition Assay		IC50=5.09887 μM	SANGER
8505C		Growth Inhibition Assay		IC50=12.885 μM	SANGER
8-MG-BA		Growth Inhibition Assay		IC50=4.88557 μM	SANGER
A101D		Growth Inhibition Assay		IC50=990.19 nM	SANGER
A204		Growth Inhibition Assay		IC50=522.33 nM	SANGER
A2058		Growth Inhibition Assay		IC50=15.5638 μM	SANGER
A2780		Growth Inhibition Assay	96 h	Antiproliferative activity against human A2780 cells with PIK3CA and PTEN mutation with IC50 of 0.14 μM	18754654
A2780		Growth Inhibition Assay		IC50=4.36682 μM	SANGER
A375		Growth Inhibition Assay		IC50=5.09256 μM	SANGER
A388		Growth Inhibition Assay		IC50=6.23115 μM	SANGER
A3-KAW		Growth Inhibition Assay		IC50=40.3661 μM	SANGER
A427		Growth Inhibition Assay		IC50=17.2334 μM	SANGER
A431		Growth Inhibition Assay		IC50=2.27354 μM	SANGER
A498		Growth Inhibition Assay		IC50=1.30474 μM	SANGER
A4-Fuk		Growth Inhibition Assay		IC50=1.29993 μM	SANGER
A549		Cytotoxic Assay	72 h	IC50=6.9 μM	23059545
A549		Growth Inhibition Assay		logGI50=-6.15 M	22336246
A549		Growth Inhibition Assay		IC50=1.3997 μM	SANGER
A704		Growth Inhibition Assay		IC50=1.50785 μM	SANGER
ACHN		Growth Inhibition Assay		logGI50=-6.07 M	22336246
ACHN		Growth Inhibition Assay		IC50=24.4656 μM	SANGER
AGS		Growth Inhibition Assay		IC50=3.62464 μM	SANGER
ALL-PO		Growth Inhibition Assay		IC50=31.8428 μM	SANGER
AM-38		Growth Inhibition Assay		IC50=25.481 μM	SANGER
AN3-CA		Growth Inhibition Assay		IC50=340.37 nM	SANGER
AsPC-1		Growth Inhibition Assay		IC50=6.74507 μM	SANGER
ATN-1		Growth Inhibition Assay		IC50=6.05568 μM	SANGER
AU565		Growth Inhibition Assay		IC50=1.31863 μM	SANGER
BALL-1		Growth Inhibition Assay		IC50=37.5316 μM	SANGER
BB30-HNC		Growth Inhibition Assay		IC50=10.669 μM	SANGER
BB49-HNC		Growth Inhibition Assay		IC50=1.88692 μM	SANGER
BB65-RCC		Growth Inhibition Assay		IC50=18.669 μM	SANGER
BE-13		Growth Inhibition Assay		IC50=37.7018 μM	SANGER
Becker		Growth Inhibition Assay		IC50=3.16808 μM	SANGER
BFTC-905		Growth Inhibition Assay		IC50=1.13449 μM	SANGER
BFTC-909		Growth Inhibition Assay		IC50=1.43305 μM	SANGER
BHT-101		Growth Inhibition Assay		IC50=544.94 nM	SANGER
BHY		Growth Inhibition Assay		IC50=3.25571 μM	SANGER
BPH-1		Growth Inhibition Assay		IC50=314 nM	SANGER
BSY1		Growth Inhibition Assay		logGI50=-6.90 M	22336246
BT-20		Growth Inhibition Assay		IC50=1.68902 μM	SANGER
BT-474		Growth Inhibition Assay		IC50=4.76384 μM	SANGER
BxPC-3		Growth Inhibition Assay		IC50=6.08219 μM	SANGER
C2BBe1		Growth Inhibition Assay		IC50=39.818 μM	SANGER
C32		Growth Inhibition Assay		IC50=3.41508 μM	SANGER
C-33-A		Growth Inhibition Assay		IC50=9.43988 μM	SANGER
Ca9-22		Growth Inhibition Assay		IC50=14.6054 μM	SANGER
CAKI-1		Growth Inhibition Assay		IC50=14.0132 μM	SANGER
CAL-120		Growth Inhibition Assay		IC50=27.6914 μM	SANGER
CAL-12T		Growth Inhibition Assay		IC50=4.41413 μM	SANGER
CAL-33		Growth Inhibition Assay		IC50=4.52456 μM	SANGER
CAL-39		Growth Inhibition Assay		IC50=2.0328 μM	SANGER
CAL-51		Growth Inhibition Assay		IC50=4.71082 μM	SANGER
CAL-54		Growth Inhibition Assay		IC50=1.07081 μM	SANGER
CAL-62		Growth Inhibition Assay		IC50=5.18259 μM	SANGER
CAL-72		Growth Inhibition Assay		IC50=14.7783 μM	SANGER
CAL-85-1		Growth Inhibition Assay		IC50=27.2118 μM	SANGER
Calu-3		Growth Inhibition Assay		IC50=3.71287 μM	SANGER
CAMA-1		Growth Inhibition Assay		IC50=38.9691 μM	SANGER
CAN		Growth Inhibition Assay		IC50=5.9282 μM	SANGER
CaR-1		Growth Inhibition Assay		IC50=6.46373 μM	SANGER
CAS-1		Growth Inhibition Assay		IC50=15.066 μM	SANGER
Ca-Ski		Growth Inhibition Assay		IC50=44.8114 μM	SANGER
CFPAC-1		Growth Inhibition Assay		IC50=42.5211 μM	SANGER
CGT		Growth Inhibition Assay		IC50=6.73681 μM	SANGER
CGTH-W-1		Growth Inhibition Assay		IC50=9.49384 μM	SANGER
CHL-1		Growth Inhibition Assay		IC50=378.65 nM	SANGER
CHP-134		Growth Inhibition Assay		IC50=13.1158 μM	SANGER
CHP-212		Growth Inhibition Assay		IC50=2.18442 μM	SANGER
COLO-678		Growth Inhibition Assay		IC50=37.9437 μM	SANGER
COLO-684		Growth Inhibition Assay		IC50=523.11 nM	SANGER
COLO-792		Growth Inhibition Assay		IC50=42.8961 μM	SANGER
COLO-800		Growth Inhibition Assay		IC50=8.04162 μM	SANGER
COLO-824		Growth Inhibition Assay		IC50=25.5599 μM	SANGER
COLO-829		Growth Inhibition Assay		IC50=33.3467 μM	SANGER
COR-L23		Growth Inhibition Assay		IC50=3.37279 μM	SANGER
CP50-MEL-B		Growth Inhibition Assay		IC50=5.68684 μM	SANGER
CTB-1		Growth Inhibition Assay		IC50=1.14293 μM	SANGER
D-247MG		Growth Inhibition Assay		IC50=10.0568 μM	SANGER
D-263MG		Growth Inhibition Assay		IC50=718.1 nM	SANGER
D-283MED		Growth Inhibition Assay		IC50=2.35926 μM	SANGER
D-423MG		Growth Inhibition Assay		IC50=1.09962 μM	SANGER
D-502MG		Growth Inhibition Assay		IC50=2.32461 μM	SANGER
D-566MG		Growth Inhibition Assay		IC50=1.6253 μM	SANGER
Daoy		Growth Inhibition Assay		IC50=7.94321 μM	SANGER
DB		Growth Inhibition Assay		IC50=13.8384 μM	SANGER
DBTRG-05MG		Growth Inhibition Assay		IC50=8.91217 μM	SANGER
DEL		Growth Inhibition Assay		IC50=10.3794 μM	SANGER
Detroit562		Growth Inhibition Assay		IC50=15.9139 μM	SANGER
DJM-1		Growth Inhibition Assay		IC50=10.6949 μM	SANGER
DK-MG		Growth Inhibition Assay		IC50=4.3039 μM	SANGER
DMS114		Growth Inhibition Assay		logGI50=-5.92 M	22336246
DMS-114		Growth Inhibition Assay		IC50=4.23891 μM	SANGER
DMS273		Growth Inhibition Assay		logGI50=-6.43 M	22336246
DMS-273		Growth Inhibition Assay		IC50=2.8647 μM	SANGER
DOHH-2		Growth Inhibition Assay		IC50=5.42248 μM	SANGER
DOK		Growth Inhibition Assay		IC50=301.7 nM	SANGER
DSH1		Growth Inhibition Assay		IC50=11.7606 μM	SANGER
DU145		Growth Inhibition Assay		logGI50=-5.85 M	22336246
DU-4475		Growth Inhibition Assay		IC50=11.7393 μM	SANGER
EFM-19		Growth Inhibition Assay		IC50=1.6181 μM	SANGER
EFO-21		Growth Inhibition Assay		IC50=9.77382 μM	SANGER
EFO-27		Growth Inhibition Assay		IC50=14.7622 μM	SANGER
EGI-1		Growth Inhibition Assay		IC50=1.84701 μM	SANGER
EKVX		Growth Inhibition Assay		IC50=1.0129 μM	SANGER
EM-2		Growth Inhibition Assay		IC50=2.51169 μM	SANGER
EPCL-272H		Growth Inhibition Assay		IC50=687.21 nM	SANGER
ES1		Growth Inhibition Assay		IC50=2.21326 μM	SANGER
ES3		Growth Inhibition Assay		IC50=30.3733 μM	SANGER
ES4		Growth Inhibition Assay		IC50=639.54 nM	SANGER
ES5		Growth Inhibition Assay		IC50=50.21 nM	SANGER
ES6		Growth Inhibition Assay		IC50=8.73119 μM	SANGER
ES7		Growth Inhibition Assay		IC50=341.99 nM	SANGER
ES8		Growth Inhibition Assay		IC50=810.52 nM	SANGER
ESS-1		Growth Inhibition Assay		IC50=5.97869 μM	SANGER
ETK-1		Growth Inhibition Assay		IC50=4.37052 μM	SANGER
EW-1		Growth Inhibition Assay		IC50=7.36996 μM	SANGER
EW-11		Growth Inhibition Assay		IC50=11.9474 μM	SANGER
EW-13		Growth Inhibition Assay		IC50=7.89977 μM	SANGER
EW-16		Growth Inhibition Assay		IC50=1.85182 μM	SANGER
EW-22		Growth Inhibition Assay		IC50=2.25067 μM	SANGER
FADU		Growth Inhibition Assay		IC50=4.37467 μM	SANGER
FTC-133		Growth Inhibition Assay		IC50=32.706 μM	SANGER
G-401		Growth Inhibition Assay		IC50=1.62164 μM	SANGER
G-402		Growth Inhibition Assay		IC50=1.89797 μM	SANGER
GAMG		Growth Inhibition Assay		IC50=370.85 nM	SANGER
GB-1		Growth Inhibition Assay		IC50=8.06565 μM	SANGER
GCIY		Growth Inhibition Assay		IC50=433.8 nM	SANGER
GI-1		Growth Inhibition Assay		IC50=14.0658 μM	SANGER
GI-ME-N		Growth Inhibition Assay		IC50=20.3373 μM	SANGER
GOTO		Growth Inhibition Assay		IC50=33.5258 μM	SANGER
GP5d		Growth Inhibition Assay		IC50=15.0474 μM	SANGER
GR-ST		Growth Inhibition Assay		IC50=5.38322 μM	SANGER
GT3TKB		Growth Inhibition Assay		IC50=16.1981 μM	SANGER
H4		Growth Inhibition Assay		IC50=850.85 nM	SANGER
H460		Cytotoxic Assay	72 h	IC50=0.87 μM	23059545
HAL-01		Growth Inhibition Assay		IC50=206.73 nM	SANGER
HBC4		Growth Inhibition Assay		logGI50=-6.03 M	22336246
HBC5		Growth Inhibition Assay		logGI50=-6.60 M	22336246
HCC1187		Growth Inhibition Assay		IC50=11.8588 μM	SANGER
HCC1395		Growth Inhibition Assay		IC50=18.5611 μM	SANGER
HCC1419		Growth Inhibition Assay		IC50=2.21115 μM	SANGER
HCC1569		Growth Inhibition Assay		IC50=11.7678 μM	SANGER
HCC-1954		Growth Inhibition Assay		IC50=37.2729 μM	SANGER
HCC2157		Growth Inhibition Assay		IC50=2.32927 μM	SANGER
HCC2998		Growth Inhibition Assay		logGI50=-6.29 M	22336246
HCC70		Growth Inhibition Assay		IC50=2.86589 μM	SANGER
HCE-4		Growth Inhibition Assay		IC50=4.27197 μM	SANGER
HCE-T		Growth Inhibition Assay		IC50=13.2364 μM	SANGER
HCT116		Growth Inhibition Assay		logGI50=-5.87 M	22336246
HCT-116		Growth Inhibition Assay		IC50=30.5554 μM	SANGER
HCT15		Growth Inhibition Assay		logGI50=-6.12 M	22336246
HDLM-2		Growth Inhibition Assay		IC50=949.2 nM	SANGER
HD-MY-Z		Growth Inhibition Assay		IC50=21.3696 μM	SANGER
HEC-1		Growth Inhibition Assay		IC50=11.4328 μM	SANGER
H-EMC-SS		Growth Inhibition Assay		IC50=13.9139 μM	SANGER
HepG2		Cytotoxic Assay	72 h	IC50=1 μM	23059545
HGC-27		Growth Inhibition Assay		IC50=212.57 nM	SANGER
HH		Growth Inhibition Assay		IC50=111.08 nM	SANGER
HL-60		Growth Inhibition Assay		IC50=425.75 nM	SANGER
HLE		Growth Inhibition Assay		IC50=8.93785 μM	SANGER
HN		Growth Inhibition Assay		IC50=3.06636 μM	SANGER
HO-1-N-1		Growth Inhibition Assay		IC50=659.17 nM	SANGER
HOP-92		Growth Inhibition Assay		IC50=2.74717 μM	SANGER
HOS		Growth Inhibition Assay		IC50=1.97948 μM	SANGER
HPAF-II		Growth Inhibition Assay		IC50=3.10068 μM	SANGER
Hs-578-T		Growth Inhibition Assay		IC50=1.19565 μM	SANGER
HSC-2		Growth Inhibition Assay		IC50=7.42705 μM	SANGER
HSC-3		Growth Inhibition Assay		IC50=839.54 nM	SANGER
HT		Growth Inhibition Assay		IC50=1.13478 μM	SANGER
HT-1080		Growth Inhibition Assay		IC50=3.08606 μM	SANGER
HT-1197		Growth Inhibition Assay		IC50=20.2958 μM	SANGER
HT-1376		Growth Inhibition Assay		IC50=7.87778 μM	SANGER
HT-29		Cytotoxic Assay	72 h	IC50=0.66 μM	23059545
HT-29		Growth Inhibition Assay		logGI50=-6.30 M	22336246
HT-3		Growth Inhibition Assay		IC50=2.49259 μM	SANGER
HT55		Growth Inhibition Assay		IC50=10.6205 μM	SANGER
HTC-C3		Growth Inhibition Assay		IC50=3.29352 μM	SANGER
HuCCT1		Growth Inhibition Assay		IC50=11.1281 μM	SANGER
HuH-7		Growth Inhibition Assay		IC50=1.20949 μM	SANGER
HuO-3N1		Growth Inhibition Assay		IC50=642.38 nM	SANGER
HuO9		Growth Inhibition Assay		IC50=206.02 nM	SANGER
HuP-T4		Growth Inhibition Assay		IC50=1.60778 μM	SANGER
IA-LM		Growth Inhibition Assay		IC50=4.99435 μM	SANGER
IGROV-1		Growth Inhibition Assay		IC50=634.31 nM	SANGER
IST-MEL1		Growth Inhibition Assay		IC50=17.9182 μM	SANGER
IST-MES1		Growth Inhibition Assay		IC50=49.5625 μM	SANGER
J82		Growth Inhibition Assay		IC50=8.29491 μM	SANGER
JEG-3		Growth Inhibition Assay		IC50=26.6805 μM	SANGER
J-RT3-T3-5		Growth Inhibition Assay		IC50=26.3027 μM	SANGER
JVM-3		Growth Inhibition Assay		IC50=1.64875 μM	SANGER
KALS-1		Growth Inhibition Assay		IC50=12.8553 μM	SANGER
KARPAS-299		Growth Inhibition Assay		IC50=23.3887 μM	SANGER
KG-1		Growth Inhibition Assay		IC50=25.5494 μM	SANGER
KGN		Growth Inhibition Assay		IC50=48.3063 μM	SANGER
KINGS-1		Growth Inhibition Assay		IC50=8.92938 μM	SANGER
KLE		Growth Inhibition Assay		IC50=9.70009 μM	SANGER
KM12		Growth Inhibition Assay		logGI50=-5.76 M	22336246
KM-H2		Growth Inhibition Assay		IC50=16.3646 μM	SANGER
KNS-62		Growth Inhibition Assay		IC50=3.92338 μM	SANGER
KNS-81-FD		Growth Inhibition Assay		IC50=35.663 μM	SANGER
KOSC-2		Growth Inhibition Assay		IC50=16.1125 μM	SANGER
KP-4		Growth Inhibition Assay		IC50=19.8531 μM	SANGER
KP-N-YS		Growth Inhibition Assay		IC50=34.7202 μM	SANGER
KS-1		Growth Inhibition Assay		IC50=2.11001 μM	SANGER
KU-19-19		Growth Inhibition Assay		IC50=516.07 nM	SANGER
KURAMOCHI		Growth Inhibition Assay		IC50=17.3897 μM	SANGER
KYSE-140		Growth Inhibition Assay		IC50=40.7165 μM	SANGER
KYSE-150		Growth Inhibition Assay		IC50=6.12476 μM	SANGER
KYSE-270		Growth Inhibition Assay		IC50=1.29734 μM	SANGER
KYSE-450		Growth Inhibition Assay		IC50=27.9862 μM	SANGER
KYSE-510		Growth Inhibition Assay		IC50=7.08432 μM	SANGER
KYSE-520		Growth Inhibition Assay		IC50=4.87392 μM	SANGER
KYSE-70		Growth Inhibition Assay		IC50=9.88011 μM	SANGER
L-363		Growth Inhibition Assay		IC50=798.42 nM	SANGER
LAMA-84		Growth Inhibition Assay		IC50=2.02689 μM	SANGER
LB1047-RCC		Growth Inhibition Assay		IC50=522.93 nM	SANGER
LB2241-RCC		Growth Inhibition Assay		IC50=303.84 nM	SANGER
LB2518-MEL		Growth Inhibition Assay		IC50=12.059 μM	SANGER
LB771-HNC		Growth Inhibition Assay		IC50=16.4422 μM	SANGER
LB-831-BLC		Growth Inhibition Assay		IC50=13.6246 μM	SANGER
LB996-RCC		Growth Inhibition Assay		IC50=1.22177 μM	SANGER
LC-2-ad		Growth Inhibition Assay		IC50=5.78251 μM	SANGER
LCLC-103H		Growth Inhibition Assay		IC50=34.1624 μM	SANGER
LCLC-97TM1		Growth Inhibition Assay		IC50=2.69267 μM	SANGER
LK-2		Growth Inhibition Assay		IC50=34.5708 μM	SANGER
LN-405		Growth Inhibition Assay		IC50=4.15728 μM	SANGER
LNCaP-Clone-FGC		Growth Inhibition Assay		IC50=796.34 nM	SANGER
LoVo		Growth Inhibition Assay		IC50=777.9 nM	SANGER
LOXIMVI		Growth Inhibition Assay		logGI50=-6.29 M	22336246
LOXIMVI		Growth Inhibition Assay		IC50=2.04084 μM	SANGER
LS-123		Growth Inhibition Assay		IC50=6.40521 μM	SANGER
LS-411N		Growth Inhibition Assay		IC50=49.3118 μM	SANGER
LS-513		Growth Inhibition Assay		IC50=18.9228 μM	SANGER
LU-134-A		Growth Inhibition Assay		IC50=4.52745 μM	SANGER
LU-99A		Growth Inhibition Assay		IC50=4.4606 μM	SANGER
LXF-289		Growth Inhibition Assay		IC50=448.27 nM	SANGER
M059J		Growth Inhibition Assay		IC50=24.5634 μM	SANGER
M14		Growth Inhibition Assay		IC50=3.30663 μM	SANGER
MC116		Growth Inhibition Assay		IC50=10.6655 μM	SANGER
MCF7	1 μM	Growth Inhibition Assay	96 h	GI50=0.0702 μM	23360348
MCF7		Growth Inhibition Assay		logGI50=-7.33 M	22336246
MCF7		Growth Inhibition Assay		IC50=898.59 nM	SANGER
MCF7.1		Growth Inhibition Assay	72 h	Antiproliferative activity against human MCF7.1 cells expressing HER2 gene with IC50 of 0.28 μM	21981714
MCF7.1		Growth Inhibition Assay	72 h	Antiproliferative activity against human MCF7.1 cells expressing PI3Kalpha mutant with EC50 of 0.39 μM	21985639
MCF7.1		Growth Inhibition Assay	72 h	Antiproliferative activity against human MCF7.1 cells expressing PI3Kalpha mutant with IC50 of 0.34 μM	20050669
MCF7.1		Growth Inhibition Assay	72 h	EC50=0.72 μM	20346656
MCF7-neo/Her2		Growth Inhibition Assay	72 h	IC50=0.29 μM	23662903
MCF7-neo/Her2		Kinase Assay		Inhibition of PI3Kalpha assessed as reduction of AKT phosphorylation at S473 with IC50 of 0.007 μM	23662903
MC-IXC		Growth Inhibition Assay		IC50=7.41972 μM	SANGER
MDA-MB-157		Growth Inhibition Assay		IC50=2.82023 μM	SANGER
MDA-MB-175-VII		Growth Inhibition Assay		IC50=352.92 nM	SANGER
MDA-MB-231		Growth Inhibition Assay		logGI50=-5.46 M	22336246
MDA-MB-231		Growth Inhibition Assay		IC50=16.7136 μM	SANGER
MDA-MB-361		Function Assay	2 h	Inhibition of Akt Ser473 phosphorylation in human MDA-MB-361 cells with PIK3CA E545-K mutation with IC50 of 0.028 μM	18754654
MDA-MB-361		Growth Inhibition Assay	96 h	Antiproliferative activity against human MDA-MB-361 cells with PIK3CA E545-K mutation with IC50 of 0.72 μM	18754654
MDA-MB-361		Growth Inhibition Assay		IC50=439.13 nM	SANGER
MDA-MB-415		Growth Inhibition Assay		IC50=1.48692 μM	SANGER
MDA-MB-453		Growth Inhibition Assay		IC50=17.0003 μM	SANGER
ME-180		Growth Inhibition Assay		IC50=1.93477 μM	SANGER
MEL-HO		Growth Inhibition Assay		IC50=2.67634 μM	SANGER
Mewo		Growth Inhibition Assay		IC50=3.42182 μM	SANGER
MFE-280		Growth Inhibition Assay		IC50=418.2 nM	SANGER
MFM-223		Growth Inhibition Assay		IC50=19.0716 μM	SANGER
MG-63		Growth Inhibition Assay		IC50=541.11 nM	SANGER
MHH-ES-1		Growth Inhibition Assay		IC50=7.07762 μM	SANGER
MHH-NB-11		Growth Inhibition Assay		IC50=9.01839 μM	SANGER
MHH-PREB-1		Growth Inhibition Assay		IC50=114.3 nM	SANGER
MKN1		Growth Inhibition Assay		logGI50=-7.08 M	22336246
MKN1		Growth Inhibition Assay		IC50=5.07927 μM	SANGER
MKN28		Growth Inhibition Assay		logGI50=-5.52 M	22336246
MKN45		Growth Inhibition Assay		logGI50=-6.55 M	22336246
MKN7		Growth Inhibition Assay		logGI50=-6.50 M	22336246
MKN7		Growth Inhibition Assay		IC50=2.70754 μM	SANGER
MKN74		Growth Inhibition Assay		logGI50=-6.02 M	22336246
MLMA		Growth Inhibition Assay		IC50=16.5571 μM	SANGER
MN-60		Growth Inhibition Assay		IC50=9.24542 μM	SANGER
MOLT-16		Growth Inhibition Assay		IC50=41.1536 μM	SANGER
MOLT-4		Growth Inhibition Assay		IC50=623.62 nM	SANGER
MPP-89		Growth Inhibition Assay		IC50=10.0946 μM	SANGER
MS-1		Growth Inhibition Assay		IC50=8.61387 μM	SANGER
MSTO-211H		Growth Inhibition Assay		IC50=11.0716 μM	SANGER
MV-4-11		Growth Inhibition Assay		IC50=724.31 nM	SANGER
MZ2-MEL		Growth Inhibition Assay		IC50=3.66138 μM	SANGER
NB10		Growth Inhibition Assay		IC50=5.22744 μM	SANGER
NB12		Growth Inhibition Assay		IC50=2.84914 μM	SANGER
NB13		Growth Inhibition Assay		IC50=19.8839 μM	SANGER
NB14		Growth Inhibition Assay		IC50=42.7027 μM	SANGER
NB5		Growth Inhibition Assay		IC50=956.6 nM	SANGER
NB69		Growth Inhibition Assay		IC50=245.27 nM	SANGER
NB7		Growth Inhibition Assay		IC50=389.83 nM	SANGER
NBsusSR		Growth Inhibition Assay		IC50=488.85 nM	SANGER
NCI-H1048		Growth Inhibition Assay		IC50=2.1052 μM	SANGER
NCI-H1092		Growth Inhibition Assay		IC50=5.41148 μM	SANGER
NCI-H1155		Growth Inhibition Assay		IC50=25.5847 μM	SANGER
NCI-H1355		Growth Inhibition Assay		IC50=4.55146 μM	SANGER
NCI-H1395		Growth Inhibition Assay		IC50=27.7833 μM	SANGER
NCI-H1437		Growth Inhibition Assay		IC50=6.24073 μM	SANGER
NCI-H1563		Growth Inhibition Assay		IC50=915.99 nM	SANGER
NCI-H1623		Growth Inhibition Assay		IC50=304.08 nM	SANGER
NCI-H1648		Growth Inhibition Assay		IC50=998.51 nM	SANGER
NCI-H1650		Growth Inhibition Assay		IC50=23.9241 μM	SANGER
NCI-H1666		Growth Inhibition Assay		IC50=2.51104 μM	SANGER
NCI-H1693		Growth Inhibition Assay		IC50=30.5942 μM	SANGER
NCI-H1755		Growth Inhibition Assay		IC50=6.36612 μM	SANGER
NCI-H1770		Growth Inhibition Assay		IC50=123.86 nM	SANGER
NCI-H1792		Growth Inhibition Assay		IC50=7.51711 μM	SANGER
NCI-H1793		Growth Inhibition Assay		IC50=18.1581 μM	SANGER
NCI-H1975		Cytotoxic Assay	72 h	IC50=0.27 μM	23059545
NCI-H2029		Growth Inhibition Assay		IC50=20.3266 μM	SANGER
NCI-H2030		Growth Inhibition Assay		IC50=2.24123 μM	SANGER
NCI-H2126		Growth Inhibition Assay		IC50=4.24558 μM	SANGER
NCI-H2170		Growth Inhibition Assay		IC50=31.5784 μM	SANGER
NCI-H2228		Growth Inhibition Assay		IC50=1.85203 μM	SANGER
NCI-H226		Cytotoxic Assay	72 h	IC50=2.9 μM	23059545
NCI-H226		Growth Inhibition Assay		logGI50=-6.21 M	22336246
NCI-H2291		Growth Inhibition Assay		IC50=8.29187 μM	SANGER
NCI-H23		Growth Inhibition Assay		logGI50=-5.73 M	22336246
NCI-H2342		Growth Inhibition Assay		IC50=7.5149 μM	SANGER
NCI-H2347		Growth Inhibition Assay		IC50=32.4837 μM	SANGER
NCI-H2452		Growth Inhibition Assay		IC50=27.7716 μM	SANGER
NCI-H28		Growth Inhibition Assay		IC50=3.05291 μM	SANGER
NCI-H292		Growth Inhibition Assay		IC50=974.32 nM	SANGER
NCI-H358		Growth Inhibition Assay		IC50=49.3018 μM	SANGER
NCI-H441		Growth Inhibition Assay		IC50=25.7465 μM	SANGER
NCI-H446		Growth Inhibition Assay		IC50=9.361 μM	SANGER
NCI-H460		Growth Inhibition Assay		IC50=10.2806 μM	SANGER
NCI-H483		Growth Inhibition Assay		logGI50=-6.56 M	22336246
NCI-H520		Growth Inhibition Assay		IC50=1.08967 μM	SANGER
NCI-H522		Growth Inhibition Assay		logGI50=-6.58 M	22336246
NCI-H522		Growth Inhibition Assay		IC50=44.3568 μM	SANGER
NCI-H526		Growth Inhibition Assay		IC50=1.9139 μM	SANGER
NCI-H596		Growth Inhibition Assay		IC50=8.31453 μM	SANGER
NCI-H650		Growth Inhibition Assay		IC50=11.3794 μM	SANGER
NCI-H661		Growth Inhibition Assay		IC50=32.0623 μM	SANGER
NCI-H727		Growth Inhibition Assay		IC50=19.3295 μM	SANGER
NCI-H747		Growth Inhibition Assay		IC50=4.05638 μM	SANGER
NCI-N87		Growth Inhibition Assay		IC50=2.13384 μM	SANGER
NCI-SNU-1		Growth Inhibition Assay		IC50=35.179 μM	SANGER
NEC8		Growth Inhibition Assay		IC50=653.57 nM	SANGER
NH-12		Growth Inhibition Assay		IC50=2.05424 μM	SANGER
NKM-1		Growth Inhibition Assay		IC50=593.09 nM	SANGER
NMC-G1		Growth Inhibition Assay		IC50=11.1493 μM	SANGER
no-11		Growth Inhibition Assay		IC50=7.90174 μM	SANGER
NOMO-1		Growth Inhibition Assay		IC50=10.3532 μM	SANGER
NOS-1		Growth Inhibition Assay		IC50=211.82 nM	SANGER
NTERA-S-cl-D1		Growth Inhibition Assay		IC50=21.6722 μM	SANGER
NUGC-3		Growth Inhibition Assay		IC50=18.6584 μM	SANGER
OAW-28		Growth Inhibition Assay		IC50=38.639 μM	SANGER
OAW-42		Growth Inhibition Assay		IC50=872.19 nM	SANGER
OC-314		Growth Inhibition Assay		IC50=5.37444 μM	SANGER
OCUB-M		Growth Inhibition Assay		IC50=13.8156 μM	SANGER
OE19		Growth Inhibition Assay		IC50=16.524 μM	SANGER
OE33		Growth Inhibition Assay		IC50=4.70511 μM	SANGER
OMC-1		Growth Inhibition Assay		IC50=751.09 nM	SANGER
OVCAR3		Growth Inhibition Assay		logGI50=-6.71 M	22336246
OVCAR-3		Growth Inhibition Assay		IC50=20.5822 μM	SANGER
OVCAR4		Growth Inhibition Assay		logGI50=-5.76 M	22336246
OVCAR-4		Growth Inhibition Assay		IC50=13.6524 μM	SANGER
OVCAR5		Growth Inhibition Assay		logGI50=-6.26 M	22336246
OVCAR-5		Growth Inhibition Assay		IC50=940.17 nM	SANGER
OVCAR8		Growth Inhibition Assay		logGI50=-5.73 M	22336246
OVCAR-8		Growth Inhibition Assay		IC50=4.22543 μM	SANGER
P12-ICHIKAWA		Growth Inhibition Assay		IC50=5.401 μM	SANGER
P30-OHK		Growth Inhibition Assay		IC50=730.71 nM	SANGER
PA-1		Growth Inhibition Assay		IC50=532.41 nM	SANGER
PANC-03-27		Growth Inhibition Assay		IC50=1.51408 μM	SANGER
PANC-08-13		Growth Inhibition Assay		IC50=15.6859 μM	SANGER
PANC-10-05		Growth Inhibition Assay		IC50=16.0821 μM	SANGER
PC-14		Growth Inhibition Assay		IC50=3.73222 μM	SANGER
PC3		Function Assay	2 h	Inhibition of Akt Ser473 phosphorylation in PTEN-null human PC3 cells with IC50 of 0.037 μM	18754654
PC3		Growth Inhibition Assay	96 h	IC50=0.28 μM	18754654
PC3		Growth Inhibition Assay	72 h	IC50=0.28 μM	21981714
PC3		Growth Inhibition Assay	72 h	EC50=0.34 μM	21985639
PC3		Growth Inhibition Assay	72 h	Antiproliferative activity against human PC3 cells deficient in PTEN with IC50 of 0.39 μM	20050669
PC3		Growth Inhibition Assay		logGI50=-6.66 M	22336246
PC-3		Growth Inhibition Assay		IC50=5.91615 μM	SANGER
PFSK-1		Growth Inhibition Assay		IC50=1.94458 μM	SANGER
PSN1		Growth Inhibition Assay		IC50=5.38286 μM	SANGER
QIMR-WIL		Growth Inhibition Assay		IC50=865.2 nM	SANGER
Ramos-2G6-4C10		Growth Inhibition Assay		IC50=1.60746 μM	SANGER
RAW 264.7		Kinase Assay	90 min	Inhibition of human PI3Kgamma expressed assessed as inhibition of AKT phosphorylation with IC50 of 0.298 μM	22548342
RCC10RGB		Growth Inhibition Assay		IC50=11.135 μM	SANGER
RCM-1		Growth Inhibition Assay		IC50=9.63801 μM	SANGER
RD		Growth Inhibition Assay		IC50=8.59391 μM	SANGER
RERF-LC-MS		Growth Inhibition Assay		IC50=8.34856 μM	SANGER
RH-1		Growth Inhibition Assay		IC50=43.4836 μM	SANGER
RH-18		Growth Inhibition Assay		IC50=8.35046 μM	SANGER
RKO		Growth Inhibition Assay		IC50=26.7632 μM	SANGER
RMG-I		Growth Inhibition Assay		IC50=18.7382 μM	SANGER
RO82-W-1		Growth Inhibition Assay		IC50=4.32584 μM	SANGER
RPMI-2650		Growth Inhibition Assay		IC50=3.60637 μM	SANGER
RPMI-7951		Growth Inhibition Assay		IC50=4.57002 μM	SANGER
RPMI-8226		Growth Inhibition Assay		IC50=5.05461 μM	SANGER
RPMI-8866		Growth Inhibition Assay		IC50=6.19163 μM	SANGER
RS4-11		Growth Inhibition Assay		IC50=261.76 nM	SANGER
RT-112		Growth Inhibition Assay		IC50=6.60338 μM	SANGER
RVH-421		Growth Inhibition Assay		IC50=10.1505 μM	SANGER
RXF393		Growth Inhibition Assay		IC50=9.47002 μM	SANGER
RXF631L		Growth Inhibition Assay		logGI50=-6.88 M	22336246
S-117		Growth Inhibition Assay		IC50=29.3857 μM	SANGER
Saos-2		Growth Inhibition Assay		IC50=1.33205 μM	SANGER
SAS		Growth Inhibition Assay		IC50=9.25581 μM	SANGER
SBC-5		Growth Inhibition Assay		IC50=6.97297 μM	SANGER
SCC-25		Growth Inhibition Assay		IC50=914.19 nM	SANGER
SCC-4		Growth Inhibition Assay		IC50=5.41355 μM	SANGER
SCC-9		Growth Inhibition Assay		IC50=36.7146 μM	SANGER
SCH		Growth Inhibition Assay		IC50=22.496 μM	SANGER
SF126		Growth Inhibition Assay		IC50=2.30625 μM	SANGER
SF268		Growth Inhibition Assay		logGI50=-5.39 M	22336246
SF268		Growth Inhibition Assay		IC50=16.452 μM	SANGER
SF295		Growth Inhibition Assay		logGI50=-6.37 M	22336246
SF295		Growth Inhibition Assay		IC50=2.31524 μM	SANGER
SF539		Growth Inhibition Assay		logGI50=-6.50 M	22336246
SF539		Growth Inhibition Assay		IC50=6.99333 μM	SANGER
Sf9		Kinase Assay	1 h	Inhibition of human recombinant PI3K p110delta expressed in Sf9 cells coexpressing p85alpha with IC50 of 0.003 μM	18754654
Sf9		Kinase Assay	1 h	Inhibition of human recombinant PI3K p110beta H1047-R mutant expressed in Sf9 cells coexpressing p85alpha with IC50 of 0.003 μM	18754654
Sf9		Kinase Assay	1 h	Inhibition of human recombinant PI3K p110beta E545-K mutant expressed in Sf9 cells coexpressing p85alpha with IC50 of 0.003 μM	18754654
Sf9		Kinase Assay	1 h	Inhibition of human recombinant PI3K p110beta expressed in Sf9 cells coexpressing p85alpha with IC50 of 0.033 μM	18754654
Sf9		Kinase Assay	1 h	Inhibition of human recombinant PI3K p110alpha expressed in Sf9 cells coexpressing p85alpha	18754654
Sf9		Kinase Assay	30 min	Inhibition of human PI3Kgamma expressed assessed as amount of ATP consumed with IC50 of 0.042 μM	22548342
Sf9		Kinase Assay	1 h	Inhibition of GST-fused human recombinant PI3Kbeta expressed in baculovirus infected SF9 cells with IC50 of 0.017 μM	23540645
Sf9		Kinase Assay	1 h	Inhibition of GST-fused human recombinant PI3Kdelta expressed	23540645
Sf9		Kinase Assay	1 h	Inhibition of GST-fused human recombinant PI3Kgamma expressed	23540645
Sf9		Kinase Assay	1 h	Inhibition of GST-fused human recombinant PI3Kalpha expressed	23540645
SGC7901		Cytotoxic Assay	72 h	IC50=1.8 μM	23059545
SH-4		Growth Inhibition Assay		IC50=36.73 μM	SANGER
SiHa		Growth Inhibition Assay		IC50=34.3817 μM	SANGER
SJRH30		Growth Inhibition Assay		IC50=8.15878 μM	SANGER
SJSA-1		Growth Inhibition Assay		IC50=3.71315 μM	SANGER
SKG-IIIa		Growth Inhibition Assay		IC50=2.65939 μM	SANGER
SK-LU-1		Growth Inhibition Assay		IC50=2.44586 μM	SANGER
SK-MEL-1		Growth Inhibition Assay		IC50=1.30679 μM	SANGER
SK-MEL-2		Growth Inhibition Assay		IC50=17.3213 μM	SANGER
SK-MEL-24		Growth Inhibition Assay		IC50=40.5931 μM	SANGER
SK-MEL-28		Growth Inhibition Assay		IC50=1.56085 μM	SANGER
SK-MEL-3		Growth Inhibition Assay		IC50=38.2397 μM	SANGER
SK-MES-1		Growth Inhibition Assay		IC50=2.01332 μM	SANGER
SK-N-DZ		Growth Inhibition Assay		IC50=13.0453 μM	SANGER
SK-NEP-1		Growth Inhibition Assay		IC50=725.94 nM	SANGER
SK-N-FI		Growth Inhibition Assay		IC50=4.25332 μM	SANGER
SKOV3	1 μM	Kinase Assay	1 h	Inhibition of PI3Kalpha assessed as inhibition of Akt Ser473 phosphorylation	23360348
SKOV3	1 μM	Growth Inhibition Assay	96 h	GI50=0.1476 μM	23360348
SKOV3		Growth Inhibition Assay		logGI50=-6.52 M	22336246
SK-OV-3		Growth Inhibition Assay		IC50=7.39432 μM	SANGER
SN12C		Growth Inhibition Assay		IC50=9.65338 μM	SANGER
SNB75		Growth Inhibition Assay		logGI50=-7.10 M	22336246
SNB75		Growth Inhibition Assay		IC50=2.01541 μM	SANGER
SNB78		Growth Inhibition Assay		logGI50=-6.52 M	22336246
SNU-387		Growth Inhibition Assay		IC50=3.16364 μM	SANGER
SNU-423		Growth Inhibition Assay		IC50=2.40171 μM	SANGER
SNU-449		Growth Inhibition Assay		IC50=2.57014 μM	SANGER
SNU-C2B		Growth Inhibition Assay		IC50=17.0237 μM	SANGER
St-4		Growth Inhibition Assay		logGI50=-5.56 M	22336246
SW1088		Growth Inhibition Assay		IC50=2.49213 μM	SANGER
SW13		Growth Inhibition Assay		IC50=29.8519 μM	SANGER
SW1573		Growth Inhibition Assay		IC50=3.75348 μM	SANGER
SW1710		Growth Inhibition Assay		IC50=1.04233 μM	SANGER
SW1783		Growth Inhibition Assay		IC50=4.75308 μM	SANGER
SW48		Growth Inhibition Assay		IC50=8.59453 μM	SANGER
SW626		Growth Inhibition Assay		IC50=6.73946 μM	SANGER
SW684		Growth Inhibition Assay		IC50=5.66385 μM	SANGER
SW756		Growth Inhibition Assay		IC50=13.7246 μM	SANGER
SW780		Growth Inhibition Assay		IC50=6.2042 μM	SANGER
SW837		Growth Inhibition Assay		IC50=11.0949 μM	SANGER
SW872		Growth Inhibition Assay		IC50=727.89 nM	SANGER
SW954		Growth Inhibition Assay		IC50=4.99443 μM	SANGER
SW962		Growth Inhibition Assay		IC50=3.72636 μM	SANGER
SW982		Growth Inhibition Assay		IC50=13.8276 μM	SANGER
T47D		Growth Inhibition Assay		IC50=597.56 nM	SANGER
T98G		Growth Inhibition Assay		IC50=1.99006 μM	SANGER
TCCSUP		Growth Inhibition Assay		IC50=4.24788 μM	SANGER
TE-1		Growth Inhibition Assay		IC50=4.66143 μM	SANGER
TE-12		Growth Inhibition Assay		IC50=8.77505 μM	SANGER
TE-5		Growth Inhibition Assay		IC50=14.7208 μM	SANGER
TE-6		Growth Inhibition Assay		IC50=5.41816 μM	SANGER
TE-8		Growth Inhibition Assay		IC50=3.48259 μM	SANGER
TGBC1TKB		Growth Inhibition Assay		IC50=4.45113 μM	SANGER
TGBC24TKB		Growth Inhibition Assay		IC50=1.08045 μM	SANGER
TGW		Growth Inhibition Assay		IC50=16.8102 μM	SANGER
TI-73		Growth Inhibition Assay		IC50=7.06285 μM	SANGER
TK10		Growth Inhibition Assay		IC50=1.67083 μM	SANGER
TYK-nu		Growth Inhibition Assay		IC50=1.95823 μM	SANGER
U-118-MG		Growth Inhibition Assay		IC50=10.9896 μM	SANGER
U251		Growth Inhibition Assay		logGI50=-5.50 M	22336246
U-2-OS		Growth Inhibition Assay		IC50=3.13782 μM	SANGER
U87MG		Function Assay	2 h	Inhibition of Akt Ser473 phosphorylation in PTEN-null human U87MG cells with IC50 of 0.046 μM	18754654
U87MG		Growth Inhibition Assay	96 h	IC50=0.95 μM	18754654
U87MG		Cytotoxic Assay	72 h	IC50=7.77 μM	23059545
U-87-MG		Growth Inhibition Assay		IC50=9.24321 μM	SANGER
UACC-62		Growth Inhibition Assay		IC50=48.4072 μM	SANGER
UACC-893		Growth Inhibition Assay		IC50=19.9757 μM	SANGER
UM-UC-3		Growth Inhibition Assay		IC50=5.72231 μM	SANGER
VA-ES-BJ		Growth Inhibition Assay		IC50=1.6127 μM	SANGER
VM-CUB-1		Growth Inhibition Assay		IC50=30.6413 μM	SANGER
VMRC-RCZ		Growth Inhibition Assay		IC50=14.0015 μM	SANGER
WM-115		Growth Inhibition Assay		IC50=1.06656 μM	SANGER
YAPC		Growth Inhibition Assay		IC50=33.8159 μM	SANGER
YH-13		Growth Inhibition Assay		IC50=304.32 nM	SANGER
YKG-1		Growth Inhibition Assay		IC50=3.03787 μM	SANGER
ZR-75-30		Growth Inhibition Assay		IC50=10.9441 μM	SANGER

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02430363	Glioblastoma	Phase 1 Phase 2	Unknown	June 2018	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Belgium UCL- Cliniques Universitaires Saint Luc Brussels, Belgium Germany St Johannes Hospital Duisburg, Germany, 47166 Italy Spedali Civili di Brescia Brescia, Italy IRCCS San Raffaele Milan, Italy Poland Lower-Silesian Oncology Centre Wroclaw, Lower-Silesian, Poland, 53413 Russian Federation Pavlov State Medical University St. Petersburg, Russian Federation, 197089 Spain Hospital Universitario Germans Trias I Pujol Barcelona,, Spain Switzerland Universitätsklinik für Frauenheilkunde Bern, Switzerland Ukraine Regional Cancer Center Dnepropetrovsk, Ukraine, 49000 National Institute of Cancer Kiev, Ukraine, 03035 United Kingdom Royal Victoria Hospital Belfast, Ulster, United Kingdom, BT12 6BA 收起 <<
NCT02389842	Advanced Solid Tumours ... 展开 >> Breast Cancer 收起 <<	Phase 1	Unknown	August 2017	United Kingdom ... 展开 >> The Royal Marsden NHS Foundation Trust Recruiting London, United Kingdom, SM2 5PT Contact: Timothy Yap, PhD 02086613539 timothy.yap@icr.ac.uk Principal Investigator: Timothy Yap, PhD The Christie NHS Foundation Trust Not yet recruiting Manchester, United Kingdom, M20 4BX Contact: Anne Amstrong, MBBS 0161 446 3746 elaine.mercer@christie.nhs.uk Principal Investigator: Anne Armstrong, MBBS 收起 <<
NCT02092831	Healthy Volunteer	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Madison, Wisconsin, United States, 53704 收起 <<
NCT00960960	Breast Cancer	Phase 1	Completed	-	United States, Illinois ... 展开 >> Peoria, Illinois, United States, 61615 United States, Massachusetts Boston, Massachusetts, United States, 02115 United States, Tennessee Nashville, Tennessee, United States, 37232 Belgium Leuven, Belgium, 3000 Italy Milano, Lombardia, Italy, 20133 收起 <<
NCT00974584	Non-Squamous Non-Small Cell Lu... 展开 >>ng Cancer 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Buffalo, New York, United States, 14263 France Villejuif, France, 94805 Netherlands Groningen, Netherlands, 9700 RB 收起 <<
NCT01493843	Non-Small Cell Lung Cancer	Phase 2	Completed	-	-
NCT00999128	Healthy Volunteers	Phase 1	Completed	-	United States, California ... 展开 >> Genentech Trial Information Support South San Francisco, California, United States, 94080 收起 <<
NCT01437566	Breast Cancer	Phase 2	Completed	-	-
NCT00996892	Solid Tumors	Phase 1	Terminated(A recommended Phase... 展开 >> 2 dose and schedule was not identified and the study was terminated before initiation of Stage 2B.) 收起 <<	-	United States, Maryland ... 展开 >> Baltimore, Maryland, United States, 21231 United States, Massachusetts Boston, Massachusetts, United States, 02114 Boston, Massachusetts, United States, 02215 United States, Michigan Detroit, Michigan, United States, 48201 United States, Oklahoma Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Nashville, Tennessee, United States, 37203 收起 <<
NCT00928330	Metastatic Breast Cancer	Phase 1	Completed	-	United States, Indiana ... 展开 >> Indianapolis, Indiana, United States, 46202 United States, Maryland Baltimore, Maryland, United States, 21231 United States, Massachusetts Boston, Massachusetts, United States, 02115 收起 <<
NCT01240226	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... 展开 >> Investigational Site Austin, Texas, United States, 78744 收起 <<
NCT00975182	Non-Squamous Non-Small Cell Lu... 展开 >>ng Cancer, Solid Cancers 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> Aurora, Colorado, United States, 80045 United States, New Jersey New Brunswick, New Jersey, United States, 08903 Netherlands Amsterdam, Netherlands, 1066 EC Utrecht, Netherlands, 3508 GA 收起 <<
NCT01474668	Healthy Volunteer	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Madison, Wisconsin, United States, 53704-2523 收起 <<
NCT00996892	-		Terminated(A recommended Phase... 展开 >> 2 dose and schedule was not identified and the study was terminated before initiation of Stage 2B.) 收起 <<	-	-
NCT00876122	Non-Hodgkin's Lymphoma, Solid ... 展开 >>Cancers 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Sutton, United Kingdom, SM2 5PT 收起 <<
NCT01918306	Estrogen Receptor Negative Bre... 展开 >>ast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Triple Negative Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer Triple-negative Breast Cancer 收起 <<	Phase 1 Phase 2	Terminated(company stopped pro... 展开 >>duction of study drug due to excessive toxicities, lack of efficacy) 收起 <<	-	United States, Alabama ... 展开 >> University of Alabama Birmingham, Alabama, United States United States, California University of California, San Francisco San Francisco, California, United States United States, District of Columbia Georgetown University Washington, D.C., District of Columbia, United States United States, Georgia Emory University Atlanta, Georgia, United States United States, Illinois University of Chicago Chicago, Illinois, United States United States, Indiana Indiana University Indianapolis, Indiana, United States United States, Maryland John Hopkins University Baltimore, Maryland, United States United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States United States, Michigan University of Michigan Ann Arbor, Michigan, United States United States, Minnesota Mayo Clinic Rochester, Minnesota, United States United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States United States, North Carolina University of North Carolina Charlotte, North Carolina, United States United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas Baylor Breast Center Houston, Texas, United States United States, Washington University of Washington Seattle, Washington, United States 收起 <<
NCT01740336	Breast Cancer	Phase 2	Completed	-	-
NCT01918306	-		Terminated(company stopped pro... 展开 >>duction of study drug due to excessive toxicities, lack of efficacy) 收起 <<	-	-
NCT00876109	Solid Cancers	Phase 1	Completed	-	United States, Arizona ... 展开 >> Scottsdale, Arizona, United States, 85258 United States, Massachusetts Boston, Massachusetts, United States, 02215 United States, Michigan Detroit, Michigan, United States, 48201 收起 <<

Pictilisib {[allProObj[0].p_purity_real_show]}

Pictilisib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Pictilisib 质控信息

Pictilisib 生物活性

Pictilisib 细胞实验

Pictilisib 动物实验

Pictilisib 动物研究

Pictilisib 临床研究

Pictilisib 参考文献

Pictilisib 实验方案

Pictilisib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Pictilisib {[allProObj[0].p_purity_real_show]}

Pictilisib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Pictilisib 质控信息

Pictilisib 生物活性

Pictilisib 细胞实验

Pictilisib 动物实验

Pictilisib 动物研究

Pictilisib 临床研究

Pictilisib 参考文献

Pictilisib 实验方案

Pictilisib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Pictilisib 纯度/质量文件产品仅供科研